- Home
- MTLS vs MNPR Comparison
MTLS vs MNPR Comparison
Compare MTLS & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- MNPR
- Stock Information
- Founded
- MTLS 1990
- MNPR 2014
- Country
- MTLS Belgium
- MNPR United States
- Employees
- MTLS N/A
- MNPR N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- MTLS Technology
- MNPR Health Care
- Exchange
- MTLS Nasdaq
- MNPR Nasdaq
- Market Cap
- MTLS N/A
- MNPR 244.1M
- IPO Year
- MTLS 2014
- MNPR 2019
- Fundamental
- Price
- MTLS $4.79
- MNPR $33.43
- Analyst Decision
- MTLS Buy
- MNPR Strong Buy
- Analyst Count
- MTLS 1
- MNPR 5
- Target Price
- MTLS $9.50
- MNPR $49.60
- AVG Volume (30 Days)
- MTLS 201.3K
- MNPR 30.2K
- Earning Date
- MTLS 04-24-2025
- MNPR 05-08-2025
- Dividend Yield
- MTLS N/A
- MNPR N/A
- EPS Growth
- MTLS 106.79
- MNPR N/A
- EPS
- MTLS 0.24
- MNPR N/A
- Revenue
- MTLS $276,182,835.00
- MNPR N/A
- Revenue This Year
- MTLS $6.55
- MNPR N/A
- Revenue Next Year
- MTLS $9.21
- MNPR N/A
- P/E Ratio
- MTLS $20.89
- MNPR N/A
- Revenue Growth
- MTLS 4.15
- MNPR N/A
- 52 Week Low
- MTLS $4.70
- MNPR $1.72
- 52 Week High
- MTLS $9.69
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- MTLS 31.61
- MNPR 45.29
- Support Level
- MTLS $4.81
- MNPR $36.80
- Resistance Level
- MTLS $5.25
- MNPR $43.00
- Average True Range (ATR)
- MTLS 0.16
- MNPR 5.63
- MACD
- MTLS 0.08
- MNPR 0.16
- Stochastic Oscillator
- MTLS 13.85
- MNPR 21.49
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.